EverPoint Asset Management’s Pacira BioSciences PCRX Stock Holding History

EverPoint Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.23M	Buy	+100,000	New	+$3.34M	0.06%	291
2016 Q3	–	Sell	-265,000	Closed	-$8.94M	–	480
2016 Q2	$8.94M	Buy	+265,000	New	+$13M	0.18%	160
2014 Q4	–	Sell	-60,000	Closed	-$5.82M	–	521
2014 Q3	$5.82M	Sell	60,000 -5,000	-8%	-$486K	0.13%	233
2014 Q2	$5.97M	Buy	+65,000	New	+$4.95M	0.12%	236

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EverPoint Asset Management's PCRX Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Pacira BioSciences (PCRX) in Q4 2016: 100,000 shares worth $3.23M. The stake represents 0.06% of the portfolio and ranks #291 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in PCRX as recently as Q2 2016.

EverPoint Asset Management first reported a position in PCRX in Q2 2014 and has held it in 4 quarters since. The position peaked at $8.94M in Q2 2016. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

EverPoint Asset Management held 100,000 shares of Pacira BioSciences worth $3.23M as of Q4 2016.
Pacira BioSciences was a new EverPoint Asset Management position in Q4 2016.
Pacira BioSciences made up 0.06% of EverPoint Asset Management's portfolio in Q4 2016, its #291 holding.
EverPoint Asset Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 4 quarters since.
EverPoint Asset Management's Pacira BioSciences position peaked at $8.94M in Q2 2016.
182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.